The Right Antibiotic Can Save You From Addiction

By Jomana F. Musmar, PhD, MS - Chief Executive Officer & Co-Founder, ASC;
Founder & Senior Consultant, Advisors of Global Health, LLC

March 6, 2026

The traditional narrative of the opioid crisis often focuses on the backend: rehabilitation, recovery, and the struggle of long-term dependency. However, the most effective way to combat the epidemic is to prevent the cycle from ever starting. For many patients, the journey toward opioid dependency begins in the hospital bed, fueled by inadequately managed acute pain.

Surprisingly, one of our strongest allies in this fight isn't a new painkiller, but the targeted and appropriate use of non-analgesic medications, specifically antibiotics.

With increasing antimicrobial resistance (AMR) threatening their access, investment in novel antibiotics is urgently needed.

The Connection: Infection, Pain, and Opioids

Pain is often a symptom of an underlying biological insult. When a patient suffers from an infection—whether post-surgical or systemic—the resulting inflammatory response triggers intense nociceptive pain. Historically, if this pain weren't controlled, clinicians relied heavily on opioids to bridge the gap.

However, research shows that source control is the most effective form of pain management. By prescribing the appropriate antibiotic early, clinicians can rapidly reduce the bacterial load and the subsequent inflammatory cascade.

- **Faster Pain Relief:** Targeted antimicrobial therapy addresses the root cause of the pain rather than just masking the signal.
- **Reduced Opioid Requirements:** Early and appropriate antibiotic intervention in highly inflammatory conditions may lead to a measurable decrease in opioid usage and other pain management required by the patient during their stay.

The Innovation Gap: Why Novel Antibiotics Matter

To sustain this protective effect, we must address a growing crisis in the pharmaceutical pipeline: the lack of novel antibiotic development. As antimicrobial resistance (AMR) rises, our existing "toolkit" of antibiotics is shrinking. When standard treatments fail due to resistance, patients suffer from prolonged infections, chronic inflammation, and—by extension—longer exposure to high-dose opioids.

The Right Antibiotic Can Save You From Addiction

Currently, the market for new antibiotics is economically fragile. Because new drugs are (rightfully) "stewarded" and kept as a last resort, sales are low, leading many major developers to exit the field. However, supporting the market for novel antibiotics is a direct investment in the opioid fight. Without new, effective antimicrobials to treat resistant infections, we risk a future where uncontrolled infection-related pain becomes a primary driver of new opioid dependencies.

Earlier Discharge and the "Safety Zone"

The risk of opioid addiction is often dose-dependent and time-dependent. The longer a patient remains in a clinical setting with uncontrolled pain, the higher the likelihood of a prolonged opioid prescription upon discharge.

Effective antibiotic stewardship ensures that patients meet clinical stability markers faster and optimized antibiotic regimens lead to shorter hospital stays. By getting a patient healthy and discharged earlier, we effectively narrow the "window of exposure" to high-potency hospital analgesics.

A Shift in Stewardship

When a physician chooses the right antibiotic at the right time, they aren't just treating an infection; they are proactively protecting that patient from the potential path of substance use disorder. Precision medicine in prescribing is, quite literally, a preventative measure against addiction.

We often talk about Antibiotic Stewardship to prevent resistance, and Opioid Stewardship to prevent addiction. It is time we recognize them as two sides of the same coin.

References

- Chahine EB. The Role of Pharmacists in the Fight Against COVID-19. *Sr Care Pharm*. 2020 Jul 1;35(7):286-291.
- Keane OA, Motley T, Robinson J, Smith A, Short HL, Santore MT. Standardization of Antibiotic Management and Reduction of Opioid Prescribing in Pediatric Complicated Appendicitis: A Quality Improvement Initiative. *J Pediatr Surg*. 2024 Jun;59(6):1058-1065.
- Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2014 Jul 15;59(2):147-59.